Rituximab as treatment for minimal residual disease in hairy cell leukaemia: Extended follow-up

British Journal of Haematology

Volumn 143, Issue 2, 2008, Pages 296-298

  Cervetti, Giulia ^a   Galimberti, Sara ^a   Andreazzoli, Francesca ^a   Fazzi, Rita ^a   Cecconi, Nadia ^a   Caracciolo, Francesco ^a   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cladribrine; HCL; Minimal residual disease; Rituximab

Indexed keywords

CD20 ANTIGEN; CLADRIBINE; PURINE DERIVATIVE; RITUXIMAB;

ADULT; AGED; BONE MARROW BIOPSY; CANCER RELAPSE; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; FEMALE; FEVER; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LEUKEMIA; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SPLENECTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; TREATMENT OUTCOME;

EID: 52649089106     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07333.x     Document Type: Letter

References (10)

1. Cervetti, G., Galimberti, S., Andreazzoli, F., Fazzi, R., Cecconi, N., Caracciolo, F. Petrini, M. (2004) Rituximab as treatment for minimal residual disease in hairy cell leukaemia. European Journal of Haematology, 73, 412 417.
2. Hagberg, H. Lundholm, L. (2001) Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. British Journal of Haematology, 115, 609 611.
3. Hoffman, M. Auerbach, L. (2000) Bone marrow remission of hairy cell leukaemia induced by Rituximab (anti-C20 monoclonal antibody) in a patient refractory to cladribrine. British Journal of Haematology, 109, 900 901.
4. Johnson, P. Glennie, M. (2003) The mechanism of action of Rituximab in the elimination of tumor cells. Seminars in Oncology, 30 (Suppl. 2 3 8.
5. Juliusson, G., Lenkei, R. Liliemark, J. (1994) Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood, 83, 3672 3681.
6. Piro, L.D., Carrera, C.J., Carson, D.A. Beutler, E. (1990) Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New England Journal of Medicine, 322, 1117 1121.
7. Ravandi, F., Jorgensen, J.L., O'Brien, S.M, Verstovsek, S., Koller, C.A., Faderl, S., Giles, F.J., Ferrajoli, A., Wierda, W.G., Odinga, S., Huang, X., Thomas, D.A., Freireich, E.J., Jones, D., Keating, M.J. Kantarjian, A.M. (2006) Eradication of minimal residual disease in hairy cell leukemia. Blood, 107, 4658 4662.
8. Tallman, M.S., Hakimian, D., Rademaker, A.W., Zanzig, C., Wollins, E., Rose, E. Peterson, L.C. (1996) Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow up of the Northwestern University experience. Blood, 88, 1954 1959.
9. Thomas., D.A., O'Brien, S., Bueso-Ramos, C., Faderl, S., Keating, M.J., Giles, F.G., Cortes, J Kantarjian, H.M. (2003) Rituximab in relapsed or refractory Hairy Cell Leukemia. Blood, 102, 3906 3911.
10. Wheaton, S., Tallman, M.S., Hakimian, D. Peterson, L. (1996) Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood, 87, 1556 1560.